Mito-TEMPO-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMito-TEMPOCat.No.:HY-112879CASNo.:1334850-99-5分?式:C??H??ClN?O?P分?量:510.03作?靶點(diǎn):MitochondrialMetabolism;ReactiveOxygenSpecies作?通路:MetabolicEnzyme/Protease;Immunology/Inflammation;NF-κB儲(chǔ)存?式:-20°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:125mg/mL(245.08mM;Needultrasonic)H2O:60mg/mL(117.64mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.9607mL9.8033mL19.6067mL5mM0.3921mL1.9607mL3.9213mL10mM0.1961mL0.9803mL1.9607mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.25mg/mL(4.41mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.25mg/mL(4.41mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.25mg/mL(4.41mM);Clearsolution4.請(qǐng)依序添加每種溶劑：PBSSolubility:50mg/mL(98.03mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Mito-TEMPO?種靶向線粒體的超氧化物歧化酶模擬物，有除超氧化物和烷?由的能?。體內(nèi)研究Mito-TEMPO(MT)greatlyattenuatestheincreaseinALTactivitiesandreducestheareasofnecrosisatbothtimepoints,indicatingthattheprotectionbyMito-TEMPOissustaineduntilatleast24hpost-APAP.Mito-TempocouldinducesecondaryapoptosisinthelatephaseofAPAPhepatotoxicity.Mito-TempoinducessecondaryapoptosisafterAPAPoverdosebyinhibitionofRIP3[1].PROTOCOLAnimalMice[1]Administration[1]MaleC57BL/6Jmice(8-12weeks)andRIP3-deficientmice(C57BL/6Nbackground)areusedthroughoutthestudy.Themiceareacclimatedbeforeexperimentswithfreeaccesstodietandwater.Overnight-fastedmice(16-18h)aretreatedi.p.with300mg/kgAPAPdissolvedinwarmsaline.Somemicearetreatedwith200mg/kgAPAPinexperimentsevaluatingeffectofRIP3deficiency.Adoseof20mg/kgMito-Tempodissolvedinsalineisadministeredi.p.1.5or3hafterAPAP.Somemicearesubsequentlytreated(i.p.)with10mg/kgZVDfmkdissolvedinTris-bufferedsalineorvehicle2hafterAPAP.TomimictheclinicalcareofAPAP-overdosepatients,somemicereceivetheantidoteNAC(i.p.,500mg/kg)at1.5or3hafterAPAPoverdose[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?ActaPharmSinB.21July2021.?JHazardMater.15February2022,127268.?BasicResCardiol.2022Aug23;117(1):40.?RedoxBiol.2020Jul;34:101559.?IntJBiolSci.2022Mar6;18(6):2261-2276.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].DuK,etal.Mito-tempoprotectsagainstacuteliverinjurybutinduceslimitedsecondaryapoptosisduringthelatephaseof2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEacetaminophenhepatotoxicity.ArchToxicol.2018Oct15.McePdfHeightCaution:Producthasnotbeenful